SIGNIFICANT FUNDING ANNOUNCED FOR NSW RESEARCHERS Garvan, UNSW Sydney, University of Sydney researchers receive 8 year Snow Foundation Fellowships
SEGMENT
Filmed in Sydney | April 2026
The Snow Medical Research Foundation (Snow Medical) has announced a new $24 million investment in three outstanding Australian biomedical researchers through its prestigious Snow Fellowships.
The fellowships will support Dr Deborah Burnett from UNSW, Associate Professor Sudarshini Ramanathan from the University of Sydney, and Dr Ira Deveson from the Garvan Institute of Medical Research.
These Fellows will tackle major global health challenges spanning autoimmune disease, neurological disorders, and genetic disease. Their work addresses conditions that disproportionately affect vulnerable and underserved populations, including First Nations communities, while advancing precision medicine and translational care. Collectively, their research aims to deliver safer vaccines, better diagnostics, and more equitable genomic and neurological healthcare.
The investment further strengthens New South Wales as a global hub for biomedical research, bringing Snow Medical’s total investment in the state to $128 million, with $89.5 million committed in the past year alone.
Each Snow Medical Fellowship provides $8 million over eight years, enabling exceptional scientists to pursue ambitious long-term research programs, build world-class teams, and tackle complex scientific challenges.
Chair of Snow Medical Research Foundation, Tom Snow, said the fellowships reflect the Snow family’s commitment to backing bold scientific ideas and supporting outstanding young researchers and clinicians.
Snow Fellows receive active scientific and leadership mentoring during their fellowship, including executive and team coaching and a strategic development program. The program builds Fellows’ management and leadership skills and instils a strategic and entrepreneurial mindset.
BACKGROUNDS TO THE THREE SNOW FELLOWS FOR 2026
Dr Deborah Burnett – UNSW
Dr Deborah Burnett is an immunology researcher working to improve vaccine effectiveness against infections that can trigger autoimmune disease.
Associate Professor Sudarshini Ramanathan – University of Sydney
Associate Professor Sudarshini Ramanathan is a neurologist and clinician scientist whose work focuses on autoimmune neurological disorders. Her research has helped identify new neurological syndromes and improve diagnostic tools and treatments for patients with autoimmune diseases affecting the brain, spinal cord, muscles and nerves. Her work aims to reverse disabilities in these patients through the use of targeted therapies.
Dr Ira Deveson – Garvan Institute of Medical Research
Dr Ira Deveson is a genomics researcher whose work focuses on developing and applying advanced genomic sequencing technologies to better understand human genetic diversity and improve diagnosis and treatment of inherited disease. His program is helping unravel the genetic diversity of Australia’s Indigenous populations to ensure equity in genomic medicine.
Source: Adapted from Snow Medical Research Foundation news story
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
-
Improving access to osteopathic services and integrated care models
The Chief Executive Officer of Osteopathy Australia, Antony Nicholas spoke with Australian Health Journal about:
– Involvement in the Strengthening Medicare Task Force
– The unique skills osteopaths have that can address the chronic disease burden
– Current workforce issues around osteopaths and if enough are coming through via student placements
– How uploading data to My Health Record by osteopaths could assist team-based care of patients
– How the value of osteopaths in Residential Aged Care Facilities (RACFs) could be better understood and better access for residents
– The recommendations around aged care access to allied health services, including osteopathy
– The recommendations around consumer access to osteopaths and GP referrals
– Other osteopathy recommendations in the upcoming Federal BudgetIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
